15236
N,O-Bis(trimethylsilyl)carbamate
≥98.0% (T)
동의어(들):
BSC, Trimethylsilyl N-(trimethylsilyl)carbamate
로그인조직 및 계약 가격 보기
모든 사진(1)
About This Item
Linear Formula:
(CH3)3SiNHCO2Si(CH3)3
CAS Number:
Molecular Weight:
205.40
Beilstein:
2043399
EC Number:
MDL number:
UNSPSC 코드:
12352100
PubChem Substance ID:
NACRES:
NA.22
추천 제품
Quality Level
분석
≥98.0% (T)
양식
solid
mp
77-83 °C
작용기
amine
SMILES string
C[Si](C)(C)NC(=O)O[Si](C)(C)C
InChI
1S/C7H19NO2Si2/c1-11(2,3)8-7(9)10-12(4,5)6/h1-6H3,(H,8,9)
InChI key
DGIJAZGPLFOQJE-UHFFFAOYSA-N
유사한 제품을 찾으십니까? 방문 제품 비교 안내
기타 정보
Extremely suitable reagent for the silylation of alcohols, phenols and carboxylic acids. The only by-products are CO2 and NH3; Silyloxycarbonylation of amines; Acylisocyanates from carboxylic acid chlorides
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
개인 보호 장비
dust mask type N95 (US), Eyeshields, Gloves
가장 최신 버전 중 하나를 선택하세요:
L. Birkofer et al.
Journal of Organometallic Chemistry, 99, C1 (1975)
Sudarshan Chari et al.
PLoS genetics, 9(8), e1003661-e1003661 (2013-08-13)
The phenotypic outcome of a mutation cannot be simply mapped onto the underlying DNA variant. Instead, the phenotype is a function of the allele, the genetic background in which it occurs and the environment where the mutational effects are expressed.
Yoshitaka Narita et al.
Neuro-oncology, 21(3), 348-359 (2018-12-01)
We conducted a phase III trial of personalized peptide vaccination (PPV) for human leukocyte antigen (HLA)-A24+ recurrent glioblastoma to develop a new treatment modality. We randomly assigned 88 recurrent glioblastoma patients to receive PPV (n = 58) or the placebo
M J Sorich et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 26(1), 13-21 (2014-08-15)
Monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR) prolong survival in metastatic colorectal cancer (mCRC) Kirsten rat sarcoma viral oncogene (KRAS) exon 2 wild-type tumors. Recent evidence has suggested that other RAS mutations (in exons 3 and 4
Ronak Saluja et al.
Journal of oncology practice, 14(5), e280-e294 (2018-03-31)
The purpose of this study was to determine if clinical benefits of novel anticancer drugs, measured by the ASCO Value Framework and European Society of Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale, have increased over time in parallel with
문서
Results of a study involving the ability few Fluka silylating reagents to form GC-MS-compatible trimethylsilylmethyl derivatives of NSAIDs
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.